Economic evaluation of chronic hepatitis B treatments in Taiwan

Journal of Gastroenterology and Hepatology (Australia)

Volumn 23, Issue 4, 2008, Pages 571-579

  Lacey, Laurence ^a   Chien, Rong Nan ^b   Chuang, Wan Long ^c   Pwu, Raoh Fang ^d  

^a Lacey Solutions Ltd   (Ireland)

^b CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

^c KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

^d TAIPEI MEDICAL UNIVERSITY   (Taiwan)

Author keywords

Adefovir; Chronic hepatitis B; Cost effectiveness; Lamivudine; Taiwan

Indexed keywords

ADEFOVIR; ADEFOVIR DIPIVOXIL; HEPATITIS B(E) ANTIGEN; INTERFERON; LAMIVUDINE; PEGINTERFERON ALPHA2A;

ADD ON THERAPY; ANTIVIRAL RESISTANCE; ARTICLE; COMBINATION CHEMOTHERAPY; COST BENEFIT ANALYSIS; COST OF ILLNESS; DISEASE COURSE; HEALTH CARE SYSTEM; HEALTH STATUS; HEPATITIS B; HUMAN; MONOTHERAPY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROBABILITY; QUALITY CONTROL; SURVIVAL RATE; TAIWAN; TREATMENT DURATION;

EID: 41849120786     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/j.1440-1746.2008.05360.x     Document Type: Article

References (41)

1. World Health Organisation. Hepatitis B. WHO publication WHO/CDS/CSR/LYO/2002.2: Hepatitis B. © World Health Organization, 2002. Accessed 4 Feb 2008. Available from http://www.who.int/csr/disease/hepatitis/ whocdscsrlyo20022/en/index.html
2. McMahon BJ. The natural history of chronic hepatitis B virus infection. Semin. Liver Dis. 2004 24 (Suppl. 1 17 21.
3. Chen C-J, Yang H, Su J et al. Rick of hepatocellular carcinoma across a biological gradient of serum HBV DNA level. JAMA 2006 295 : 65 73.
4. Iloeje U, Yang H, Su J et al. Predicting cirrhosis risk based on the level of circulating hepatitis B viral load. Gastroenterology 2006 130 : 678 86.
5. Liaw Y-F, Sung JJY, Chow WC et al. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N. Engl. J. Med. 2004 351 : 1521 31.
6. Sung J-L, Chen D-S, Lai M-Y et al. Epidemiological study on hepatitis B virus infection in Taiwan. Chin. J. Gastroenterol. 1984 1 : 1 9.
7. Taiwan Statistics Center, Department of Health. Accessed 06 Feb 2008. Available from http://www.doh.gov.tw/statistic/index.htm
8. Bureau of National Health Insurance. Medical Care of Liver Disease. [Press Release.] 11 November, 2003.
9. Liaw Y-F, Leung N, Guan R et al. Asian-Pacific consensus statement on the management of chronic hepatitis B: A 2005 update. Liver Int. 2005 25 : 472 89.
10. Marcellin P, Asselah T, Boyer N. Treatment of chronic hepatitis B. J. Viral Hepat. 2005 12 : 333 45.
11. Lai CL, Dienstag J, Schiff E et al. Prevalence and clinical correlates of YMDD variants during lamivudine therapy for patients with chronic hepatitis B. Clin. Infect. Dis. 2003 36 : 687 96.
12. Marcellin P, Chang TT, Lin S et al. Long term efficacy and safety of adefovir dipivoxil (ADV) 10mg in HBeAg+ chronic hepatitis B (CHB) patients: increasing serologic, virologic and biochemical response over time. Hepatology. 2004 40 (Suppl. 1 655A.
13. Locarnini S, Hatzakis A, Heathcote J et al. Management of antiviral resistance in patients with chronic hepatitis B. Antivir. Ther. 2004 9 : 679 93.
14. Kobelt G. An Introduction to Economic Evaluation. London : Office of Health Economics, 1996 21 5.
15. Lacey LF, Gane E. The cost-effectiveness of long-term antiviral therapy in the management of HBeAg-positive and HBeAg-negative chronic hepatitis B in Singapore. J. Viral Hepat. 2007 14 : 751 66.
16. Crowley SJ, Tognarini D, Desmond PV, Lees M. Cost-effectiveness analysis of lamivudine for the treatment of chronic hepatitis B. Pharmacoeconomics 2000 17 : 409 27.
17. Crowley S, Tognarini D, Desmond P et al. Introduction of lamivudine for the treatment of chronic hepatitis B: expected clinical and economic outcomes based on 4-year clinical trial data. J. Gastroenterol. Hepatol. 2002 17 : 153 64.
18. Lau GKK, Priatvisuth T, Luo KX et al. Peginterferon alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. N. Engl. J. Med. 2005 352 : 2682 95.
19. Marcellin P, Gedorge KKL, Bonino F et al. Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B. N. Engl. J. Med. 2004 351 : 1206 17.
20. Lin X, Robinson NJ, Thursz M et al. Chronic hepatitis B virus infection in the Asia-Pacific region and Africa: review of disease progression. J. Gastroenterol. Hepatol. 2005 20 : 833 43.
21. Liaw Y-F, Tai D-I, Chu C-M, Chen T-J. The development of cirrhosis in patients with chronic type B hepatitis: a prospective study. Hepatology 1988 8 : 493 6.
22. Liaw Y-F, Lin D-Y, Chen T-J, Chu C-M. Natural course after the development of cirrhosis in patients with chronic type B hepatitis: a prospective study. Liver 1989 9 : 235 41.
23. Perrillo RP, Lai C-L, Liaw Y-F et al. Predictors of HBeAg loss after lamivudine treatment for chronic hepatitis B. Hepatology 2002 36 : 186 94.
24. Chien R-N, Liaw Y-F, Atkins M. Pretherapy alanine transaminase level a determinant for hepatitis B e antigen seroconversion during lamivudine therapy in patients with chronic hepatitis B. Hepatology 1999 30 : 770 4.
25. Chang T-T, Lai C-L, Chien R-N et al. Four years of lamivudine treatment in Chinese patients with chronic hepatitis B. J. Gastroenterol. Hepatol. 2004 19 : 1276 82.
26. Chien R-N, Yeh C-T, Tsai S-L, Chu C-M, Liaw Y-F. Determinants for sustained HBeAg response to lamivudine therapy. Hepatology 2003 38 : 1267 73.
27. Leung NW, Lai C-L, Chang T-T et al. Extended lamivudine treatment in patients with chronic hepatitis B enhances hepatitis antigen seroconversion rates: results after 3 years. Hepatology 2001 33 : 1527 32.
28. Pwu R-F, Chan KA. Cost-effectiveness analysis of interferon-α in the treatment of CHB in Taiwan. J. Formos. Med. Assoc. 2002 101 : 632 41.
29. Hsieh C-R, Kuo C-W. Cost of chronic hepatitis B virus infection in Taiwan. J. Clin. Gastroenterol. 2004 38 : S148 52.
30. Leung N. Comparison of lamivudine and adefovir dipivoxil in the treatment of chronic hepatitis B. Hepat. B Annu. 2005 2 : 93 126.
31. Towse A. What is NICE's threshold? An external view. In : Devlin N, Towse A, eds. Cost-Effectiveness Thresholds: Economic and Ethical Issues. London : King's Fund/Office for Health Economics, 2002 25 30.
32. Sullivan SD, Veenstra DL, Chen P-E et al. Cost-effectiveness of peginterferon alfa-2a compared to lamivudine treatment in patients with hepatitis B e antigen positive chronic hepatitis B in Taiwan. J. Gastroenterol. Hepatol. 2007 22 : 1494 9.
33. Eichler HG, Kong SX, Gerth WC, Mavros P, Jonsson B. Use of cost-effectiveness analysis in health-care resource allocation decision-making: how are cost-effectiveness thresholds expected to emerge? Value Health 2004 7 : 518 28.
34. Department of Investment Services. Per Capita GDP of Major Countries (US$). Accessed 04 Feb 2008. Available from http://investintaiwan.nat. gov.tw/en/env/stats/per_capita_gdp.html
35. Dienstag JL, Cianciara J, Karayalcin S et al. Durability of serologic response after lamivudine treatment of chronic hepatitis B. Hepatology 2003 37 : 748 55.
36. Song BC, Suh DJ, Lee HC, Chung YH, Lee YH. Hepatitis B e antigen seroconversion after lamivudine therapy is not durable in patients with chronic hepatitis in Korea. Hepatology 2000 32 : 803 6.
37. Kanwal F, Gralnek IM, Martin P et al. Treatment alternatives for chronic hepatitis B virus infection: a cost-effectiveness analysis. Ann. Intern. Med. 2005 142 : 821 31.
38. Weitzman G, Jacobson I. Cost-effectiveness in hepatitis B. Ann. Intern. Med. 2005 142 : 757 8.
39. de Francis R, Hadengue A, Lau A et al. Consensus statement (long version). J. Hepatol. 2003 39 (Suppl. 1 S3 25.
40. Lau G, Piratvisuth T, Luo K et al. Durability of response and occurrence of late response to peginterferon alpha-2a (40kd) one year post-treatment in patients with HBeAg-positive chronic hepatitis. J. Hepatol. 2006 44 : S23.
41. Marcellin P, Bonino F, Lau G et al. The majority of patients with HBeAg-negative chronic hepatitis B treated with peginterferon alpha-2a (40kd) sustain responses 2 years post-treatment. J. Hepatol. 2006 44 : S275.